US4752603A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Plasminogen activator and pharmaceutical composition having thrombolytic activity
Assignee: KU Leuven
•
Filing: 1986-05-28
•
Granted: 1988-06-21
•
Expires: 2006-05-28
Abstract
Abstract A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melanoma cells. This new plasminogen activator has a strong thrombolytic effect and pharmaceutical compositions thereof may be used in the therapeutic treatment of thrombosis disorders.
Inventors
- 👤 Desire J. Collen
- 👤 Dingeman C. Rijken
- 👤 Osamu Matsuo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 07:10
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6459; A; A61; A61P; A61P7/00; A61P7/02; C12N1/00; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; A61K; A61K38/00; C12R; C12R2001/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/828
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
54 words
Human plasminogen activator, having thrombolytic properties, immunologically distinct from urokinase and having a specific activity of about 500,000 IU/mg. using the WHO First International Reference Preparation of t-PA (tissue plasminogen activator) as assay standard or a specific activity of about 90,000 IU/mg. using the WHO First International Reference Preparation of urokinase as assay standard.
Claim 2
Dependent Claim
54 words
Human plasminogen activator, having thrombolytic properties, immunologically distinct from urokinase and having a specific activity of about 500,000 IU/mg. using the WHO First International Reference Preparation of t-PA (tissue plasminogen activator) as assay standard or a specific activity of about 90,000 IU/mg. using the WHO First International Reference Preparation of urokinase as assay standard.
Claim 3
Dependent Claim
27 words
A pharmaceutically acceptable composition having thrombolytic activity comprising a thrombolytically effective amount of human plasminogen activator according to claim 1 and a pharmaceutically acceptable carrier or diluent.
Claim 4
Dependent Claim
34 words
A method for therapeutic treatment of thrombosis disorders comprising administering to a patient a thrombolytically effective amount of human plasminogen activator as defined in claim 1 or a composition as defined in claim 2.
References Cited (Backward Citations)
US3904480A
Cited
GB1492959A
Cited
GB1551275A
Cited
US4245051A
Cited
EP0005644A2
Cited
GB2025977A
Cited
US4259447A
Cited
US4317882A
Cited
US4370417A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-21 | 1991-12-21 | 1992-06-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-21 | 1995-12-21 | 1996-06-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-21 | 1999-12-21 | 2000-06-21 | $7700.00 | Window Closed / Lapsed |